TR199902631T2 - Aktive C proteinin islenmesi için gelistirilmis yöntemler - Google Patents

Aktive C proteinin islenmesi için gelistirilmis yöntemler

Info

Publication number
TR199902631T2
TR199902631T2 TR1999/02631T TR9902631T TR199902631T2 TR 199902631 T2 TR199902631 T2 TR 199902631T2 TR 1999/02631 T TR1999/02631 T TR 1999/02631T TR 9902631 T TR9902631 T TR 9902631T TR 199902631 T2 TR199902631 T2 TR 199902631T2
Authority
TR
Turkey
Prior art keywords
protein
improved methods
processing activated
activated
solutions
Prior art date
Application number
TR1999/02631T
Other languages
English (en)
Inventor
David Carlson Andrew
Arsay Sheliga Theodore
Clayton Baker Jeffrey
Huang Lihua
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR199902631T2 publication Critical patent/TR199902631T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Bu bulus, genis haliyle, islenme ve saflastirma esnasinda, aktive C proteininin kendi kendine bozunmasinin düsürülmesi için bir yönteme iliskindir. Bu bulus, sulu aktive C proteini çözeltilerini ve bu tür çözeltilerin islenmesi için gelistirilmis bir yöntemi temin etmektedir, bu yöntem, bu islemin, 150 mM' den daha büyük bir iyonik kuvvette ve 5.5-6.3 arasinda bir pH'da gerçeklestirilmesini içermektedir.
TR1999/02631T 1997-04-28 1998-04-24 Aktive C proteinin islenmesi için gelistirilmis yöntemler TR199902631T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28

Publications (1)

Publication Number Publication Date
TR199902631T2 true TR199902631T2 (tr) 2000-01-21

Family

ID=21936854

Family Applications (2)

Application Number Title Priority Date Filing Date
TR1999/02529T TR199902529T2 (tr) 1997-04-28 1998-04-24 Etkinlestirilmis protein C formülasyonlari.
TR1999/02631T TR199902631T2 (tr) 1997-04-28 1998-04-24 Aktive C proteinin islenmesi için gelistirilmis yöntemler

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR1999/02529T TR199902529T2 (tr) 1997-04-28 1998-04-24 Etkinlestirilmis protein C formülasyonlari.

Country Status (35)

Country Link
US (4) US6162629A (tr)
EP (2) EP0875563A3 (tr)
JP (2) JP4383546B2 (tr)
KR (2) KR100564189B1 (tr)
CN (2) CN1235638C (tr)
AR (2) AR015598A1 (tr)
AT (1) ATE285788T1 (tr)
AU (2) AU743531B2 (tr)
BR (2) BR9809304B1 (tr)
CA (2) CA2288143C (tr)
CO (2) CO4950523A1 (tr)
CZ (1) CZ298429B6 (tr)
DE (1) DE69828330T2 (tr)
DK (1) DK0875252T3 (tr)
EA (2) EA004881B1 (tr)
EG (1) EG23685A (tr)
ES (1) ES2234072T3 (tr)
HK (1) HK1016472A1 (tr)
HU (2) HU224826B1 (tr)
ID (2) ID22933A (tr)
IL (2) IL132502A0 (tr)
IN (2) IN183798B (tr)
MY (2) MY118591A (tr)
NO (2) NO995134L (tr)
NZ (2) NZ500346A (tr)
PE (2) PE86299A1 (tr)
PL (2) PL195642B1 (tr)
PT (1) PT875252E (tr)
SI (1) SI0875252T1 (tr)
SV (2) SV1998000051A (tr)
TR (2) TR199902529T2 (tr)
TW (2) TWI242443B (tr)
UA (2) UA73071C2 (tr)
WO (2) WO1998048818A1 (tr)
ZA (2) ZA983497B (tr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
KR100564189B1 (ko) 1997-04-28 2006-03-27 일라이 릴리 앤드 캄파니 활성화 프로틴ｃ의 가공을 위한 개선된 방법
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
BR9915317A (pt) * 1998-11-13 2001-08-07 Lilly Co Eli Método de tratar trombocitopenia induzida por heparina
ES2195655T3 (es) * 1998-11-20 2003-12-01 Lilly Co Eli Procedimiento para tratar fiebre hemorragica virica con proteina c.
AU1723200A (en) * 1998-11-23 2000-06-13 Eli Lilly And Company Method of treating sickle cell disease and thalassemia
ATE264113T1 (de) * 1998-12-10 2004-04-15 Lilly Co Eli Verwendung von protein c zur behandlung von thrombozytopenischer purpura und hämolytisches urämisches syndrom
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
WO2001089558A2 (en) * 2000-05-24 2001-11-29 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
CA2438652A1 (en) 2001-02-19 2002-09-06 Merck Patent Gesellschaft Mit Beschraenkter Haftung Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
AU2002354951A1 (en) * 2001-07-19 2003-03-03 Dmi Biosciences, Inc. Use of copper chelators to inhibit the inactivation of protein c
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
EP1453529A4 (en) 2001-09-19 2007-09-26 Oklahoma Med Res Found TREATMENT OF SEPSIS WITH TAFI
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
HUP0501111A2 (en) 2001-10-15 2007-12-28 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor
AU2002351756A1 (en) 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
JP2005528351A (ja) * 2002-03-08 2005-09-22 イーライ・リリー・アンド・カンパニー 活性化プロテインｃ製剤
EP2283856B1 (en) 2002-06-21 2017-09-20 Novo Nordisk Health Care AG Stabilised solid compositions of factor VIIa polypeptides
US20060198894A1 (en) * 2002-10-29 2006-09-07 Johanna Bentz Stabilized, solid-state polypeptide particles
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
WO2004112828A1 (en) * 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
US20080286279A1 (en) * 2004-03-17 2008-11-20 Chiron Corporation Treatment of Severe Community-Acquired Pneumonia by Administration of Tissue Factor Pathway Inhibitor (Tfpi)
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
CA2612859A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
US9175283B2 (en) * 2006-05-31 2015-11-03 Genzyme Corporation Use polysaccharides for promotion of enzymatic activity
CA2654761A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
ES2365832T3 (es) * 2007-03-05 2011-10-11 Cadila Healthcare Limited Composiciones que comprenden conjugados de peg-interferón alfa y rafinosa como crioprotector.
RU2476442C2 (ru) 2007-03-29 2013-02-27 Эббот Лэборетриз Кристаллические антитела против il-12 человека
CA2904458C (en) * 2007-11-30 2017-07-25 Wolfgang Fraunhofer Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
EP2242875A4 (en) * 2008-01-15 2012-04-04 Univ British Columbia PROTEIN C RS2069915 AS A SURVIVOR RESPONSE PREDICTOR AND ADMINISTRATION OF PROTEIN C OR AN ACTIVE PROTEIN C COMPOUND
NZ606283A (en) * 2008-11-28 2014-08-29 Abbvie Inc Stable antibody compositions and methods for stabilizing same
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013151727A1 (en) 2012-04-03 2013-10-10 Smith Medical Asd, Inc. Heparin-bulking agent compositions and methods thereof
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
WO2014005183A1 (en) 2012-07-04 2014-01-09 The University Of Sydney Treatment of inflammatory skin disorders
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3137102B1 (en) 2014-04-16 2021-07-14 ZZ Biotech LLC Apc for use in the treatment of abnormal cutaneous scarring
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
UA123020C2 (uk) * 2016-06-01 2021-02-03 Сервьє Айпі Юкей Лімітед Склади поліалкіленоксид-аспарагінази та способи їхнього виготовлення й використання
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインｃの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
WO1991012320A1 (en) * 1990-02-09 1991-08-22 Zymogenetics, Inc. Activated protein c with truncated light chain
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインｃバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
KR100564189B1 (ko) 1997-04-28 2006-03-27 일라이 릴리 앤드 캄파니 활성화 프로틴ｃ의 가공을 위한 개선된 방법
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
CN1235638C (zh) 2006-01-11
CN1261280A (zh) 2000-07-26
JP2001527543A (ja) 2001-12-25
CO4940438A1 (es) 2000-07-24
DK0875252T3 (da) 2005-04-25
CA2287267A1 (en) 1998-11-05
UA73071C2 (en) 2005-06-15
PL195090B1 (pl) 2007-08-31
CN1227025C (zh) 2005-11-16
AU7258998A (en) 1998-11-24
ZA983497B (en) 1999-10-25
PL195642B1 (pl) 2007-10-31
IL132325A0 (en) 2001-03-19
ID23172A (id) 2000-03-23
HUP0003401A3 (en) 2003-01-28
AR015598A1 (es) 2001-05-16
NO995134D0 (no) 1999-10-21
US6395270B1 (en) 2002-05-28
CA2288143A1 (en) 1998-11-05
ES2234072T3 (es) 2005-06-16
NO995198L (no) 1999-10-25
SV1998000050A (es) 1999-01-13
HUP0003401A2 (hu) 2001-02-28
IN187157B (tr) 2002-02-16
EG23685A (en) 2007-05-09
MY118591A (en) 2004-12-31
NO995134L (no) 1999-12-21
SI0875252T1 (en) 2005-06-30
EA002149B1 (ru) 2001-12-24
EP0875563A3 (en) 2000-08-02
ID22933A (id) 1999-12-16
KR20010020242A (ko) 2001-03-15
JP2001524111A (ja) 2001-11-27
HUP0100284A3 (en) 2003-08-28
PL336420A1 (en) 2000-06-19
EP0875563A2 (en) 1998-11-04
IL132325A (en) 2005-07-25
PE86299A1 (es) 1999-09-17
PT875252E (pt) 2005-03-31
IL132502A0 (en) 2001-03-19
ZA983496B (en) 1999-10-25
EA004881B1 (ru) 2004-08-26
PE84799A1 (es) 1999-09-16
WO1998048818A1 (en) 1998-11-05
EA199900979A1 (ru) 2000-06-26
AU740753C (en) 2002-10-10
US6162629A (en) 2000-12-19
CN1254284A (zh) 2000-05-24
DE69828330D1 (de) 2005-02-03
BR9809292A (pt) 2000-07-04
KR100450856B1 (ko) 2004-10-02
CA2287267C (en) 2006-08-15
TWI242443B (en) 2005-11-01
AU743531B2 (en) 2002-01-31
NZ500346A (en) 2001-08-31
EP0875252B1 (en) 2004-12-29
EP0875252A3 (en) 2000-07-26
TW585871B (en) 2004-05-01
DE69828330T2 (de) 2005-10-13
PL336889A1 (en) 2000-07-17
AR012010A1 (es) 2000-09-13
KR20010020325A (ko) 2001-03-15
HU224826B1 (en) 2006-02-28
CA2288143C (en) 2012-08-21
JP4383547B2 (ja) 2009-12-16
UA55448C2 (uk) 2003-04-15
HUP0100284A2 (hu) 2001-06-28
CZ298429B6 (cs) 2007-10-03
NO995198D0 (no) 1999-10-25
TR199902529T2 (tr) 2000-02-21
EP0875252A2 (en) 1998-11-04
HK1016472A1 (en) 1999-11-05
IN183798B (tr) 2000-04-15
US6159468A (en) 2000-12-12
NZ337828A (en) 2001-06-29
EA199900980A1 (ru) 2000-04-24
KR100564189B1 (ko) 2006-03-27
BR9809304A (pt) 2000-10-17
CZ381099A3 (cs) 2000-03-15
BR9809304B1 (pt) 2011-02-08
WO1998048822A1 (en) 1998-11-05
JP4383546B2 (ja) 2009-12-16
ATE285788T1 (de) 2005-01-15
AU740753B2 (en) 2001-11-15
SV1998000051A (es) 1998-12-11
CO4950523A1 (es) 2000-09-01
MY120984A (en) 2005-12-30
US6436397B1 (en) 2002-08-20
AU7161898A (en) 1998-11-24

Similar Documents

Publication Publication Date Title
TR199902631T2 (tr) Aktive C proteinin islenmesi için gelistirilmis yöntemler
BR0213786A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
BR0211200A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
DE59505786D1 (de) Verfahren zur abreicherung oder entfernung von endotoxinen
IN181859B (tr)
DE60011390D1 (de) Verfahren und vorrichtung zur identifikation oder karakterisierung von polypeptiden
TR199802441A3 (tr) Kanda asiri ürik asit bulunmasinin tedavisi ve önlenmesi için yöntem ve terkip.
ATE240743T1 (de) Verfahren und substanzen gegen protozoen
BR0209990A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
DE69530570D1 (de) Verfahren zur behandlung von stoehrungen des menschlichen oder tierischen koerpers durch verabreichung von aminosaeuren
DE69835813D1 (de) Verfahren zur kultivierung von zellen und zur vermehrung von viren
ATE242814T1 (de) Diisopropylfluorophosphatase sowie deren verwendung und herstellung
DE69415463T2 (de) Mittel zur Behandlung von Metallionen in wässriger Lösung, Verfahren zu seiner Herstellung und Verfahren zur Behandlung von Metallionen in wässriger Lösung
WO2002037122A3 (en) Sterol glucoside toxins
DE69925648D1 (de) Vorrichtung zur Behandlung von wasserstoffhaltigen Abgasen
DE69803854D1 (de) Verfahren zur aufarbeitung von säure und nitroverbindungen enthaltenden wässrigen lösungen
GR3033698T3 (en) Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections.
DE69734890D1 (de) Rdgb-proteine
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
ATE161544T1 (de) Verfahren zur aufarbeitung einer wässrigen prozessflüssigkeit des aminoxidverfahrens
ATE220678T1 (de) Verfahren zur gewinnung von hämin aus schlachtblut
SE9702993D0 (sv) Anti-mikrobial komposition
TH43277A (th) วิธีที่ถูกปรับปรุงสำหรับกระบวนการผลิตแอคติเวเตตโปรตีนซี
ECSP982488A (es) Metodos mejorados para procesamiento de proteina c activada
FR2800095B1 (fr) Procede de traitement d'une peau, et peau ainsi obtenue